All In Biotech

Drug Trial Radar · NCT03720041

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)

Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 740 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

740

Planned (sponsor's estimate)

Start

Aug 4, 2020

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Takeda; Celgene
First posted
Oct 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview: A phase III, multi-centre, randomised controlled trial to compare standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with the novel triplet ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I) in patients with newly diagnosed multiple myeloma not suitable for a stem cell transplant. All participants receive induction treatment with ixazomib, lenalidomide and dexamethasone and are randomised on a 1:1 basis at trial entry to the use of frailty score-adjusted up-front dose reductions vs. standard up-front dosing followed by toxicity dependent reactive dose-modifications during therapy. Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation on a 1:1 basis to maintenance treatment with lenalidomide plus placebo versus lenalidomide plus ixazomib. Participants and their treating physicians will be blinded to maintenance allocation. Participant population: * Newly diagnosed as having Multiple Myeloma (MM) according to the updated IMWG diagnostic criteria 2014 (see Appendix 1 for criteria) * Not eligible for stem cell transplant * Aged at least 18 years * Able to provide written informed consent Number of participants: 740 participants will be entered into the trial at Randomisation 1 (R1), with 478 participants at Randomisation 2 (R2). Objectives: The primary objectives of this study are to determine: * Early treatment cessation (within 60 days of randomisation) for standard versus frailty-adjusted up-front dosing * Progression-free survival (PFS, from maintenance randomisation) for lenalidomide + placebo (R) versus lenalidomide + ixazomib (R+I) The secondary objectives of this study are to assess progression-free survival (PFS) for standard versus frailty-adjusted up-front dosing reductions, time to progression, time to 2nd PFS event (PFS2), overall survival (OS), survival after progression, deaths within 12 months of R1, overall response rate (ORR), attainment of ≥VGPR, attainment of MRD negativity, duration of response, time to improved response, time to next treatment, treatment compliance and total amount of therapy delivered, toxicity \& safety including the incidence of SPMs, Quality of Life (QoL), cost effectiveness of standard versus frailty-adjusted up-front dosing of IRD and cost-effectiveness of R + I versus R. Exploratory objectives are prospective validation of a novel frailty risk score (UK-MRA Myeloma Risk Profile - MRP), usefulness of Karnofsky Performance Status (PS), and association of molecular subgroups with response, PFS and OS.

Conditions

  • Multiple Myeloma

Interventions

  • R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive armDrug

    In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg/day on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.

  • R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive armDrug

    In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below: 1. Fit category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally 2. Unfit category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally 3. Frail category: Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.

  • R2: Lenalidomide plus placebo maintenanceDrug

    Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses: Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15 \* or final dose administered at the end of induction treatment if lower. This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days. Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.

  • R2: Lenalidomide + ixazomib maintenanceDrug

    Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses: Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15 \* or final dose administered at the end of induction treatment if lower. This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days. Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomisation 1: Number of participants with early treatment cessationTime frame: Within 60 days of Randomisation 1
  2. Randomisation 2: Progression-free survival (PFS-R2)Time frame: The time from the date of Randomisation 2 to the date of first documented evidence of disease progression or death from any cause, up to 120 months

Locations

110 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • Nevill Hall Hospital

    Abergavenny, United Kingdom · Not yet recruiting

  • Wrightington Hosptial

    Appley Bridge, United Kingdom · Not yet recruiting

  • Ysbyty Gwynedd

    Bangor, United Kingdom · Not yet recruiting

  • North Devon District Hospital

    Barnstaple, United Kingdom · Not yet recruiting

  • Furness General Hospital

    Barrow in Furness, United Kingdom · Not yet recruiting

  • Basingstoke and North Hampshire Hospital

    Basingstoke, United Kingdom · Not yet recruiting

  • Royal United Hospital

    Bath, United Kingdom · Not yet recruiting

  • Belfast City Hospital

    Belfast, United Kingdom · Not yet recruiting

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom · Not yet recruiting

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Not yet recruiting

  • Royal Blackburn Hospital

    Blackburn, United Kingdom · Not yet recruiting

  • Blackpool Victoria Hospital

    Blackpool, United Kingdom · Recruiting

  • Royal Bolton Hospital

    Bolton, United Kingdom · Not yet recruiting

  • Pilgrim Hospital

    Boston, United Kingdom · Not yet recruiting

  • Royal Bournemouth Hospital

    Bournemouth, United Kingdom · Recruiting

  • Bradford Royal Infirmary

    Bradford, United Kingdom · Not yet recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Southmead Hospital

    Bristol, United Kingdom · Not yet recruiting

  • Queen's Hospital

    Burton-on-Trent, United Kingdom · Not yet recruiting

  • Kent and Canterbury Hospital

    Canterbury, United Kingdom · Recruiting

  • Chelmsford & Essex Hospital

    Chelmsford, United Kingdom · Not yet recruiting

  • Cheltenham General Hospital

    Cheltenham, United Kingdom · Recruiting

  • Countess of Chester Hospital

    Chester, United Kingdom · Not yet recruiting

  • St Richard's Hospital

    Chichester, United Kingdom · Not yet recruiting

  • Colchester General Hospital

    Colchester, United Kingdom · Not yet recruiting

  • University Hospital Coventry

    Coventry, United Kingdom · Not yet recruiting

  • Croydon University Hospital

    Croydon, United Kingdom · Not yet recruiting

  • Royal Derby Hospital

    Derby, United Kingdom · Not yet recruiting

  • Dorset County Hospital

    Dorchester, United Kingdom · Not yet recruiting

  • Russells Hall Hospital

    Dudley, United Kingdom · Not yet recruiting

  • Ninewells Hospital

    Dundee, United Kingdom · Not yet recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Not yet recruiting

  • Royal Devon & Exeter Hospital

    Exeter, United Kingdom · Not yet recruiting

  • Medway Maritime Hospital

    Gillingham, United Kingdom · Not yet recruiting

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom · Not yet recruiting

  • Grantham and District Hospital

    Grantham, United Kingdom · Not yet recruiting

  • Diana Princess of Wales Hospital

    Grimsby, United Kingdom · Not yet recruiting

  • Royal Surrey County Hospital

    Guildford, United Kingdom · Not yet recruiting

  • Calderdale Royal Hospital

    Halifax, United Kingdom · Not yet recruiting

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.